Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p138 | (1) | ICCBH2019

How early is early enough – Bisphosphonate treatment in Osteogenesis imperfecta

Hoyer-Kuhn Heike , Heistermann Johanna , Schonau Eckhard , Rehberg Mirko , Semler Oliver

Objective: Osteogenesis imperfecta is characterized by hereditary skeletal fragility. Bisphosphonates are the first line medical treatment in moderate and severe OI types III/IV. There is no consensus regarding treatment beginning and treatment regimen in the first years. Objective of the presented project was the evaluation of the therapeutic effect of 1 year of bisphosphonate treatment (BP; neridronate i.v. 2 mg/kg body weight every 3 months) on vertebral shape and mobility ...